Log In
Print
BCIQ
Print
Print this Print this
 

surotomycin (CB-315) (formerly CB-183,315)

  Manage Alerts
Collapse Summary General Information
Company Cubist Pharmaceuticals Inc.
DescriptionOral antibacterial lipopeptide
Molecular Target
Mechanism of Action 
Therapeutic ModalityMacrocycle
Latest Stage of DevelopmentPhase III
Standard IndicationDiarrhea (infectious)
Indication DetailsTreat Clostridium difficile-associated diarrhea (CDAD)
Regulatory Designation

U.S. - Fast Track (Treat Clostridium difficile-associated diarrhea (CDAD));
U.S. - Qualified Infectious Disease Program (Treat Clostridium difficile-associated diarrhea (CDAD))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today